- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging ...

Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as ...

Christian Howell, CEO of Cognito Therapeutics, sits down with Nasdaq’s Kristina Ayanian to discuss the company’s breakthrough approach to treating Alzheimer’s using light and sound stimulation. From ...